Apogee Therapeutics (APGE) News Today $47.25 -3.76 (-7.37%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period FY2024 EPS Estimates for Apogee Therapeutics Cut by WedbushNovember 16 at 2:31 AM | americanbankingnews.comWedbush Forecasts Lower Earnings for Apogee TherapeuticsApogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) - Analysts at Wedbush lowered their FY2024 earnings estimates for Apogee Therapeutics in a report released on Tuesday, November 12th. Wedbush analyst D. Nierengarten now expects that the company will earn ($3.10) per share for the year, down fNovember 15 at 7:35 AM | marketbeat.comApogee Therapeutics' (APGE) "Outperform" Rating Reiterated at WedbushNovember 15 at 2:59 AM | americanbankingnews.comApogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth PlansNovember 14 at 12:06 PM | finance.yahoo.comApogee Therapeutics Highlights Pipeline Progress and FinancialsNovember 13, 2024 | markets.businessinsider.comPromising Advancements and Strategic Positioning Propel Apogee Therapeutics, Inc. to a Buy RatingNovember 13, 2024 | markets.businessinsider.comApogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 | finance.yahoo.comApogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells $888,300.00 in StockNovember 11, 2024 | americanbankingnews.comApogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 6,665 SharesNovember 9, 2024 | insidertrades.comApogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 6,665 SharesApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 6,665 shares of the firm's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $59.12, for a total transaction of $394,034.80. Following the completion of the transaction, the insider now owns 267,463 shares of the company's stock, valued at $15,812,412.56. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.November 8, 2024 | marketbeat.comReviewing Apogee Therapeutics (NASDAQ:APGE) & Fennec Pharmaceuticals (NASDAQ:FENC)November 8, 2024 | americanbankingnews.comApogee Therapeutics to Participate in Upcoming November Investor ConferencesNovember 4, 2024 | globenewswire.comApogee Therapeutics, Inc. (APGE) Gets a Buy from BTIGOctober 29, 2024 | markets.businessinsider.comApogee Therapeutics price target raised to $100 from $81 at BTIGOctober 29, 2024 | markets.businessinsider.comApogee Therapeutics, Inc. (APGE) Gets a Buy from TD CowenOctober 29, 2024 | markets.businessinsider.comApogee Therapeutics, Inc. (NASDAQ:APGE) Given Average Recommendation of "Buy" by BrokeragesApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six analysts that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price obOctober 25, 2024 | marketbeat.comApogee Therapeutics' (APGE) Outperform Rating Reaffirmed at WedbushWedbush restated an "outperform" rating and set a $87.00 price target on shares of Apogee Therapeutics in a research note on Friday.October 25, 2024 | marketbeat.comApogee Therapeutics announces updated results from Phase 1 trial of APG777October 25, 2024 | markets.businessinsider.comApogee Therapeutics Unveils Promising Phase 1 Trial ResultsOctober 25, 2024 | markets.businessinsider.comWaypoint Capital Advisors LLC Invests $36.84 Million in Apogee Therapeutics, Inc. (NASDAQ:APGE)Waypoint Capital Advisors LLC purchased a new stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 627,089 shares of the company's stock, valued at approOctober 20, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Shares Down 4.1% - Should You Sell?Apogee Therapeutics (NASDAQ:APGE) Shares Down 4.1% - Here's What HappenedOctober 18, 2024 | marketbeat.comApogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific MeetingOctober 16, 2024 | globenewswire.com11,535 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Acquired by AQR Capital Management LLCAQR Capital Management LLC acquired a new position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 11,535 shares of the company's stock, vOctober 16, 2024 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) Sees Significant Decline in Short InterestApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) saw a large decrease in short interest during the month of September. As of September 30th, there was short interest totalling 7,230,000 shares, a decrease of 11.7% from the September 15th total of 8,190,000 shares. Currently, 19.9% of the company's stock are short sold. Based on an average daily volume of 423,100 shares, the short-interest ratio is presently 17.1 days.October 15, 2024 | marketbeat.comMillennium Management LLC Lowers Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)Millennium Management LLC lessened its stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 18.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 97,065 shares of the company's stock after sellOctober 14, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Has $2.82 Million Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)The Manufacturers Life Insurance Company lessened its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 15.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 71,643 shares of the company'October 9, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comApogee Therapeutics, Inc. (APGE): A Hot Stock to Buy NowOctober 7, 2024 | msn.comApogee Therapeutics CEO sells over $2.2 million in company stockOctober 6, 2024 | uk.investing.comInsider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells 6,665 Shares of StockOctober 5, 2024 | insidertrades.comApogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells $2,249,200.00 in StockOctober 5, 2024 | insidertrades.comSquarepoint Ops LLC Purchases 25,829 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)Squarepoint Ops LLC increased its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 142.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,022 shares of the company'sOctober 5, 2024 | marketbeat.comCarl Dambkowski Sells 6,665 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) StockApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 6,665 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $56.26, for a total transaction of $374,972.90. Following the sale, the insider now directly owns 274,128 shares in the company, valued at approximately $15,422,441.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.October 4, 2024 | marketbeat.comWellington Management Group LLP Increases Stake in Apogee Therapeutics IncOctober 4, 2024 | finance.yahoo.comApogee Therapeutics (NASDAQ:APGE) Shares Down 3.7% - Here's WhyApogee Therapeutics (NASDAQ:APGE) Trading Down 3.7% - Here's WhyOctober 4, 2024 | marketbeat.comMarshall Wace LLP Acquires New Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)Marshall Wace LLP bought a new position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 81,946 shares of the company's stock, valued at apOctober 3, 2024 | marketbeat.comBuy Rating on Apogee Therapeutics’ APG808: Market Potential and Treatment Advantages Amid FDA Approval LandscapeOctober 1, 2024 | markets.businessinsider.comApogee Therapeutics, Inc. (NASDAQ:APGE) Position Trimmed by Point72 Asset Management L.P.Point72 Asset Management L.P. lessened its position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 44.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 269,232 shares of the company's stockOctober 1, 2024 | marketbeat.comPerceptive Advisors LLC Grows Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)Perceptive Advisors LLC grew its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 2.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,105,636 shares of the company's stock after buyingSeptember 30, 2024 | marketbeat.comDriehaus Capital Management LLC Has $83.34 Million Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)Driehaus Capital Management LLC increased its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 2.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,117,870 shares of the company's stock after purSeptember 28, 2024 | marketbeat.comRenaissance Technologies LLC Acquires 67,504 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)Renaissance Technologies LLC boosted its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 76.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 156,204 shares of the company's stock after purchasing aSeptember 27, 2024 | marketbeat.comPoint72 DIFC Ltd Buys Shares of 16,779 Apogee Therapeutics, Inc. (NASDAQ:APGE)Point72 DIFC Ltd acquired a new stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 16,779 shares of the company's stock, valued at approximaSeptember 26, 2024 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by Affinity Asset Advisors LLCAffinity Asset Advisors LLC boosted its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 41.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 836,283 shares of the company's stock after purcSeptember 25, 2024 | marketbeat.comIntegral Health Asset Management LLC Purchases 40,000 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)Integral Health Asset Management LLC raised its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 100.0% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 80,000 shares of the company'sSeptember 23, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Trading Up 3.3%Apogee Therapeutics (NASDAQ:APGE) Trading Up 3.3%September 20, 2024 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by Victory Capital Management Inc.Victory Capital Management Inc. lifted its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 56.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 156,266 shares of the company's stock after purchasing an aSeptember 16, 2024 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by First Turn Management LLCFirst Turn Management LLC lowered its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 16.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 318,327 shares of the company's stock afSeptember 13, 2024 | marketbeat.comApogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation SummitSeptember 12, 2024 | globenewswire.comTD Asset Management Inc Reduces Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)TD Asset Management Inc trimmed its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 35.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 95,006 shares of the company's stock after selling 53,September 12, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Trading Up 5.2%Apogee Therapeutics (NASDAQ:APGE) Shares Up 5.2%September 10, 2024 | marketbeat.com Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address “This Changes Everything” - Trump Hands Millions Massive IRS Gift (Ad)Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in… >> YES! Send Me My FREE Gold Guide! APGE Media Mentions By Week APGE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APGE News Sentiment▼-0.060.56▲Average Medical News Sentiment APGE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APGE Articles This Week▼143▲APGE Articles Average Week Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ROIV News Today ASND News Today LEGN News Today ELAN News Today CYTK News Today BPMC News Today VKTX News Today RNA News Today NUVL News Today LNTH News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APGE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APGE Stock Alerts